Screener
Harrow HROW Imprimis Rx — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harrow in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Harrow’s 10-K, filed March 2, 2026.
- Filed
- Mar 2, 2026, 4:31 PM EST
- Fiscal year
- FY2025
- Accession
- 0001493152-26-008562
| Line item | Branded | Imprimis Rx | Consolidated |
|---|---|---|---|
| Gross profit | 158,526,000 | 45,843,000 | 204,369,000 |
| Operating expenses: | |||
| Selling, general and administrative | 86,324,000 | 29,373,000 | 115,697,000 |
| Research and development | 18,667,000 | 1,346,000 | 20,013,000 |
| Segment contribution | $53,535,000 | $15,124,000 | 68,659,000 |
| Corporate | 37,217,000 | ||
| Research and development | 927,000 | ||
| Income from operations | $30,515,000 |
Item 15. Exhibits, Financial Statement Schedules ITEM
FAQ
- What is Harrow's imprimis rx — operating income?
- Harrow (HROW) reported imprimis rx — operating income of $3.78M in Q4 2025.
- How has Harrow's imprimis rx — operating income changed year-over-year?
- Harrow's imprimis rx — operating income decreased by 52.6% year-over-year, from $7.98M to $3.78M.
- What is the long-term trend for Harrow's imprimis rx — operating income?
- Over 2 years (2023 to 2025), Harrow's imprimis rx — operating income has grown at a -18.5% compound annual growth rate (CAGR), from $22.78M to $15.12M.
- What does imprimis rx — operating income mean?
- Represents the profit or loss generated by a business segment after deducting all operating expenses, including COGS, SG&A, and R&D, from its revenue. It is a key measure of the segment's operational health and its ability to generate sustainable earnings. This metric excludes interest, taxes, and non-operating items to isolate core business performance.
Ask your AI about Harrow's imprimis rx — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude